Can-Fite BioPharma (CANF) Reports Q1 EPS of NIS0.06

Can-Fite BioPharma (NYSE: CANF) reported Q1 EPS of NIS0.06, versus NIS0.37 reported last year.

Clinical Development Program and Corporate Highlights Include:

• CF101 – Finalizing Design for Next Advanced Clinical Studies Can-Fite completed the design of a Phase III clinical study for the treatment of patients with rheumatoid arthritis. The Phase III design is based on positive data received from the Company's completed Phase IIb study in which CF101 was administered as a monotherapy. Can-Fite plans on submitting the Phase III study protocol to Institutional Review Boards (IRBs) for approval in the fourth quarter of 2015. Can-Fite also plans to finalize the design of its next advanced psoriasis study based on the positive data that were released recently from its further analysis of its completed Phase II/III study. Study design for the advanced psoriasis trial is expected to be completed during the second half of 2015.
• CF102 – Enrolling and Dosing Patients in Liver Cancer TrialCan-Fite continues to enroll and dose patients in its global Phase II liver cancer study. Approximately 78 patients are expected to be enrolled in the trial by the end of the first half of 2016.
• CF602 – Conducting Pre-Clinical Program and Preparatory Work for IND SubmissionCan-Fite is developing its third drug candidate, CF602, for the indication of sexual dysfunction. The Company is continuing its pre-clinical program and preparatory work for its upcoming Investigational New Drug (IND) submission that it intends to make to the U.S. FDA.
• Signed Partnership with Cipher PharmaceuticalsDuring the first quarter of 2015, Can-Fite signed a distribution agreement with Canada-based Cipher Pharmaceuticals for the distribution of CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. Following signing of the agreement, Cipher made an upfront payment of CDN$1.65 million to Can-Fite.
• Planned Acquisition of Medical Device Company by Can-Fite Subsidiary OphthaliX, Can-Fite's subsidiary, which develops ophthalmic indications of CF101, signed a non-binding term sheet to acquire Israel-based Improved Vision Systems, LTD. (I.V.S.). I.V.S. develops breakthrough medical device technology to improve sight and diagnose and offer therapy for a variety of ocular diseases and eye conditions including glaucoma, age macular degeneration (AMD), diabetic retinopathy and ocular motor pathologies, addressing multi-billion dollar markets. OphthaliX continues to enroll patients in a Phase II clinical study of CF101 for glaucoma and data release is expected during the first half of 2016.

For earnings history and earnings-related data on Can-Fite BioPharma (CANF) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Range Resources (RRC) Tops Q1 EPS by 11c; offers production guidance
• Chubb Corp. (CB) Tops Q1 EPS by 10c